Dr Reddy's Labs recalls over 3 lakh bottles of Cinacalcet tablets in US over manufacturing issues

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-11-05 08:00 GMT | Update On 2024-11-05 08:00 GMT

New Delhi: Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets, a medication used for treatment of high calcium levels in the blood and hyperparathyroidism, in the U.S. market over manufacturing issues.

The U.S. Food and Drug Administration (FDA) Enforcement Report states that Dr. Reddy's is recalling 331,590 bottles of Cinacalcet tablets in various strengths due to deviations from current good manufacturing practices (CGMP) in the American market. The recall is due to the presence of N-nitroso Cinacalcet impurity above the FDA recommended interim limit.

As per PTI, New Jersey-based Dr Reddy's Laboratories, Inc., a unit of Hyderabad-based drug major, is recalling 2,85,126 bottles of Cinacalcet tablets in 30 mg strength.

Besides, the drug maker is recalling 35,880 and 10,584 bottles of 60 mg and 90 mg strengths, respectively, USFDA said.

The affected lot has been produced in India, it added.

US-based Dr Reddy's Laboratories, Inc. initiated the Class II nationwide (US) recall on October 9 this year.

As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

The Indian pharmaceutical industry is the world's third-largest by volume and 14th-largest in value terms.

The US generic drug market was estimated to be around USD 115.2 billion in 2019. It is the largest market for pharmaceutical products.

Read also: Dr Reddy's Laboratories gets CDSCO Panel Nod To Import and Market Toripalimab 240mg solution for infusion

Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The Company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's Labs major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Dr Reddy's Labs recalls over 3 lakh bottles of Cinacalcet tablets in US over manufacturing issues

Similar News

Forum Pulls Pharmacy Chain MedPlus Over Home Sample No-Show, Slaps Rs 25,000 Fine

Fake Viagra, Cialis Sold to Americans: Mumbai Crime Branch Busts International Pharma Call-Centre Scam

Fake Bills Used to Inflate Sales: Ghaziabad Hospital Pharmacy Hit by Rs 6 Crore Scam

MSD Pharma Gets Conditional SEC Approval to Begin Phase III Trial of Sacituzumab Tirumotecan

Sanofi concludes acquisition of Vicebio

Merck division gets USFDA conditional approval for Exzolt Cattle-CA1 against cattle fever tick

Takeda announces closing of partnership with Innovent Biologics for oncology medicines

Bayer begins Phase IIa trial of BAY 3401016 for Alport Syndrome